CorMedix (NASDAQ:CRMD) Stock: Insider Joseph Todisco Buys 80,000 Shares

CorMedix Inc (NASDAQ:CRMD – Get Free Report) CEO Joseph Todisco purchased 80,000 shares of the firm’s stock in a transaction on Friday, November 13th. The shares were purchased at an average cost of $4.89 per share, for a total transaction of $391,200.00. Following the completion of the purchase, the chief executive officer directly owned 854,749 shares in the company, valued at $4,179,722.61. The trade was a 10.33% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

CorMedix Stock Performance

Shares of NASDAQ CRMD opened at $4.66 on Monday. The company has a 50-day simple moving average of $7.18 and a 200-day simple moving average of $7.57. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.56 and a quick ratio of 2.36. The company has a market cap of $363.22 million, a PE ratio of 6.75, a price-to-earnings-growth ratio of 0.90 and a beta of 1.48. CorMedix Inc has a 12 month low of $4.65 and a 12 month high of $13.02.

CorMedix (NASDAQ:CRMD – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). CorMedix had a net margin of 15.49% and a return on equity of 27.12%. The firm had revenue of $54.52 million for the quarter, compared to analysts’ expectations of $51.76 million. On average, equities analysts anticipate that CorMedix Inc will post 0.52 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Citigroup reiterated a “market outperform” rating on shares of CorMedix in a report on Tuesday, November 10th. Wall Street Zen cut CorMedix from a “hold” rating to a “sell” rating in a report on Saturday. UBS Group set a $19.00 price objective on CorMedix in a report on Tuesday, November 10th. Needham & Company LLC lifted their price objective on CorMedix from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, November 10th. Finally, Royal Bank Of Canada upped their target price on CorMedix from $14.00 to $15.00 and gave the company an “outperform” rating in a research note on Tuesday, November 10th. Eight analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.22.

Get Our Latest Analysis on CRMD

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in CorMedix in the second quarter valued at approximately $49,644,000. Marshall Wace LLP increased its position in CorMedix by 53.4% during the third quarter. Marshall Wace LLP now owns 1,195,422 shares of the company’s stock worth $9,205,000 after purchasing an additional 415,887 shares during the last quarter. Pacer Advisors Inc. increased its position in CorMedix by 128.7% during the first quarter. Pacer Advisors Inc. now owns 580,620 shares of the company’s stock worth $3,942,000 after purchasing an additional 326,724 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in CorMedix by 150.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 438,629 shares of the company’s stock worth $3,443,000 after purchasing an additional 263,618 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in CorMedix during the second quarter worth approximately $3,108,000. 34.18% of the stock is currently owned by hedge funds and other institutional investors.

CorMedix Company Profile

(Get Free Report)

CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.

Recommended Stories

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.